I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
27. April 2020 16:01 ET
|
I-Mab
SHANGHAI, China, and ROCKVILLE, Md., and MUNICH, Germany, April 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development...
I-Mab Announces Upcoming Participation at May Conferences
24. April 2020 08:13 ET
|
I-Mab
SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab Announces Upcoming Participation at April Conferences
06. April 2020 09:04 ET
|
I-Mab
SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
03. April 2020 08:08 ET
|
I-Mab
SHANGHAI, China and ROCKVILLE, MD., April 03, 2020 (GLOBE NEWSWIRE) -- I-Mab (Nasdaq: IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China
02. April 2020 08:00 ET
|
I-Mab
- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - Initiation of...
I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update
31. März 2020 07:00 ET
|
I-Mab
Successfully completed initial public offering raising approximately $114.5 million in gross proceeds Continued execution across broad pipeline portfolio; multiple clinical data readouts expected in...
I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
30. März 2020 08:25 ET
|
I-Mab
-The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with coronavirus disease ...
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology
30. März 2020 08:00 ET
|
I-Mab
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other territories -...
I-Mab Expands Global Out-Licensing and Business Development Efforts
27. März 2020 08:00 ET
|
I-Mab
Fernando J. Sallés, Ph.D., CLP®, Appointed to Lead I-Mab’s U.S. and EU Business Development SHANGHAI, China and ROCKVILLE, MD., March 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq:...
I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
23. März 2020 07:26 ET
|
I-Mab
SHANGHAI, China and ROCKVILLE, MD., March 23, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...